Patents by Inventor Constance M. Cullen

Constance M. Cullen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8383350
    Abstract: Provided are assays to measure the presence and quantity of an antibody of interest in a patient's bloodstream or other biological sample. ECL and ELISA methods, and kits for such assays, as well as anti-idiotypic antibodies provided to detect levels of the antibody in biological samples, which are from, for example, animal models and human patients.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: February 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Karen Kolz, Constance M. Cullen
  • Patent number: 6211342
    Abstract: The present invention describes a soluble fusion protein composed of a plurality of major histocompatibility complex (MHC) molecules linked together by a stabilizing structure herein referred to as the “linker,” the MHC molecules being loaded with a specific peptide or peptides. Such fusion proteins can be used as a method for stimulating or inhibiting specific T cell clones expressing T cell receptors (TCR) restricted to the specific MHC-peptide combination. Such fusion proteins can thus be used as delivery systems to stimulate T cell immunity and as a treatment for diseases such as transplant rejection or autoimmunity.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: April 3, 2001
    Assignee: Children's Hospital Medical Center
    Inventors: Raphael Hirsch, Constance M. Cullen
  • Patent number: 6197302
    Abstract: The present invention describes a soluble fusion protein composed of a plurality of major histocompatibility complex (MHC) molecules linked together by a stabilizing structure herein referred to as the “linker,” the MHC molecules being loaded with a specific peptide or peptides. Such fusion proteins can be used as a method for stimulating or inhibiting specific T cell clones expressing T cell receptors (TCR) restricted to the specific MHC-peptide combination. Such fusion proteins can thus be used as delivery systems to stimulate T cell immunity and as a treatment for diseases such as transplant rejection or autoimmunity.
    Type: Grant
    Filed: August 19, 1997
    Date of Patent: March 6, 2001
    Assignee: Children's Hospital Medical Center
    Inventors: Raphael Hirsch, Constance M. Cullen